All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

All 5 FDA-Approved Weight Loss Drugs Compared: Wegovy vs Zepbound vs Saxenda vs Contrave vs Qsymia

Complete comparison of all FDA-approved weight loss drugs: Wegovy, Zepbound, Saxenda, Contrave & Qsymia. Efficacy, costs, side effects analyzed by...

By FormBlends Editorial Research|Source reviewed by FormBlends Medical Team||

Source Reviewed

Written by FormBlends Editorial Research · Checked against primary sources by FormBlends Medical Team

All 5 FDA-Approved Weight Loss Drugs Compared: Wegovy vs Zepbound vs Saxenda vs Contrave vs Qsymia custom 2026 header image for Provider Comparisons
Custom header image for All 5 FDA-Approved Weight Loss Drugs Compared: Wegovy vs Zepbound vs Saxenda vs Contrave vs Qsymia, Provider Comparisons, and better treatment decision-making.
In This Article

This article is part of our Provider Comparisons collection. See also: GLP-1 Guides | Peptide Guides

Search and AI answer brief

Practical answer: All 5 FDA-Approved Weight Loss Drugs Compared: Wegovy vs Zepbound vs Saxenda vs Contrave vs Qsymia

Complete comparison of all FDA-approved weight loss drugs: Wegovy, Zepbound, Saxenda, Contrave & Qsymia. Efficacy, costs, side effects analyzed by...

Short answer

Complete comparison of all FDA-approved weight loss drugs: Wegovy, Zepbound, Saxenda, Contrave & Qsymia. Efficacy, costs, side effects analyzed by...

Search intent

This page answers a specific Provider Comparisons question rather than a generic overview.

What to verify

semaglutide, tirzepatide, cash price and coverage terms, safety and contraindications

How to use it

Use this information to prepare sharper questions for a licensed provider.

There are several FDA-approved prescription medications for long-term weight management, and they differ a lot in how they work and how much weight loss they produce. Here is a clear comparison of the main options.

Quick answer

The FDA-approved prescription weight-loss drugs for long-term use are orlistat (Xenical, Alli), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound). The GLP-1-class drugs, semaglutide and tirzepatide, produce the largest average weight loss, with tirzepatide leading semaglutide in head-to-head data. Older options like orlistat, Qsymia, and Contrave generally produce less weight loss but offer different mechanisms and price points. The best choice depends on your health, tolerance, and cost.

The main FDA-approved weight-loss drugs

Each works through a different mechanism.

  • Orlistat (Xenical, Alli): Blocks absorption of some dietary fat in the gut. Modest weight loss; can cause GI side effects. Alli is available over the counter at a lower dose.
  • Phentermine-topiramate (Qsymia): Combines an appetite suppressant with a drug that increases satiety. Produces moderate weight loss.
  • Naltrexone-bupropion (Contrave): Combines two drugs that act on appetite and reward pathways in the brain. Moderate weight loss.
  • Liraglutide (Saxenda): A daily GLP-1 injection that reduces appetite. More effective than older oral options, less than the newer weekly GLP-1s.
  • Semaglutide (Wegovy): A weekly GLP-1 injection with strong weight-loss results (around 15% average in trials).
  • Tirzepatide (Zepbound): A weekly dual GIP/GLP-1 injection with the largest average weight loss of the group (up to about 20%+ in trials).

Comparison table

DrugHow it worksFormRelative weight loss
Orlistat (Xenical/Alli)Blocks fat absorptionOralModest
QsymiaAppetite suppression + satietyOralModerate
ContraveAppetite/reward pathwaysOralModerate
Saxenda (liraglutide)Daily GLP-1InjectionModerate to high
Wegovy (semaglutide)Weekly GLP-1InjectionHigh (~15% avg)
Zepbound (tirzepatide)Weekly GIP + GLP-1InjectionHighest (~20%+ in trials)

Which produces the most weight loss?

The GLP-1-class drugs lead by a wide margin, and within that class, tirzepatide (Zepbound) has produced the greatest average weight loss, ahead of semaglutide (Wegovy) in head-to-head data. Liraglutide (Saxenda), an older daily GLP-1, produces less than the newer weekly options. The non-GLP-1 oral drugs (orlistat, Qsymia, Contrave) generally produce more modest results, though they remain useful options, especially where cost, tolerance, or other health factors matter.

Not sure which GLP-1 is right for you?

Take a 2-minute assessment and get a personalized recommendation after licensed provider review.

Take the Assessment →

Alternatives to Zepbound

People often ask about alternatives to Zepbound. Within the approved list, Wegovy (semaglutide) is the closest in effectiveness, followed by Saxenda (liraglutide). The oral options (Qsymia, Contrave, orlistat) are alternatives with different mechanisms and generally lower weight loss but lower cost or different side-effect profiles. The newest developments include an oral GLP-1 (orforglipron) and other pipeline drugs, so the menu of options is expanding.

How to choose

The right drug depends on several factors:

  • How much weight you want to lose. GLP-1 drugs lead for larger goals.
  • Form preference. Injection (GLP-1s) versus oral (older options).
  • Other health conditions. Some drugs suit certain conditions better and some are contraindicated in others.
  • Tolerance. Side-effect profiles differ; GLP-1s are mostly gastrointestinal.
  • Cost and coverage. GLP-1s are pricier; older oral drugs are often cheaper.

This is a decision to make with a provider who knows your full history.

Where FormBlends fits

If you are comparing weight-loss medications, FormBlends keeps plain-language guides on each option and a provider comparison tool so you can weigh effectiveness, cost, and access, including information on compounded semaglutide.

Frequently asked questions

What are the FDA-approved weight-loss drugs? Orlistat (Xenical, Alli), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound).

Which weight-loss drug works best? The GLP-1-class drugs produce the most weight loss, with tirzepatide (Zepbound) leading semaglutide (Wegovy) in head-to-head data.

What are alternatives to Zepbound? Wegovy (semaglutide) is the closest in effectiveness, then Saxenda (liraglutide). Oral options like Qsymia, Contrave, and orlistat are alternatives with different mechanisms.

Is there a generic for Wegovy? Branded semaglutide remains under patent, so there is no standard generic. Compounded semaglutide emerged as a lower-cost route during shortages.

Which weight-loss drugs are pills? Orlistat, Qsymia, and Contrave are oral. An oral GLP-1 (orforglipron) is among newer developments.

How do I compare these drugs? Look at expected weight loss, form (injection vs oral), other health conditions, side effects, and cost, with a provider's guidance.

Are the older drugs still useful? Yes. Orlistat, Qsymia, and Contrave remain options, especially where cost, tolerance, or specific health factors favor them.

Which is best for me? That depends on your goals, health, tolerance, and budget. Discuss the options with a provider to find the right fit.

Sources

  • NIDDK, prescription medications to treat overweight and obesity: https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  • New England Journal of Medicine, SURMOUNT-5 head-to-head trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2416394

Talk to a licensed provider

Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.

Start the assessment →

Research Snapshot

Head-to-head comparison
Page type
Head-to-head comparison
FormBlends review
Last reviewed
2026-05-31T23:50:00Z
FormBlends review
FormBlends official source
Official source
Saxenda evidence source
Official source
Semaglutide evidence source
Official source
Tirzepatide evidence source
Official source
Wegovy evidence source
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-05-31T23:50:00Z.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For All 5 FDA-Approved Weight Loss Drugs Compared: Wegovy vs Zepbound vs Saxenda vs Contrave vs Qsymia, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Randomized trialSemaglutide evidence2022

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight

Supports head-to-head context when pages compare older and newer GLP-1 options.

PubMed

Randomized trialTirzepatide evidence2022

Tirzepatide Once Weekly for the Treatment of Obesity

Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.

PubMed

Randomized trialTirzepatide evidence2024

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction

Used for continuation, stopping, and maintenance questions after initial weight loss.

PubMed

Randomized trialTirzepatide evidence2025

Tirzepatide for Obesity Treatment and Diabetes Prevention

Supports newer discussion of obesity treatment and diabetes-prevention outcomes.

PubMed

Systematic reviewGLP-1 class evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.

PubMed

Systematic reviewGLP-1 class evidence2025

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus

Used for pages discussing stopping therapy, weight regain, and long-term planning.

PubMed

Systematic reviewGLP-1 class evidence2025

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition

Supports body-composition, lean-mass, and metabolic-risk context.

PubMed

Comparison decision path

Use this comparison to narrow the provider review question

Direct answer

All 5 FDA-Approved Weight Loss Drugs Compared: Wegovy vs Zepbound vs Saxenda vs Contrave vs Qsymia should help you decide which option deserves a clinical review, not force a one-size answer.

Evidence check

A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.

Safety check

The right choice can change based on history, medication interactions, side effects, budget, and availability.

Next step

After comparing, use the get-started flow to route your goals and health history into the right prescription review path.

FormBlends Editorial Context

Reviewed May 14, 2026

Complete comparison of all FDA-approved weight loss drugs: Wegovy, Zepbound, Saxenda, Contrave & Qsymia. Efficacy, costs, side effects analyzed by physicians. For "All 5 FDA-Approved Weight Loss Drugs Compared: Wegovy vs Zepbound vs Saxenda vs Contrave vs Qsymia", the useful question is not just what the page says, but what a reader should confirm afterward. The page is oriented around comparison and decision support and the specifics of semaglutide, tirzepatide, cost and coverage, side effects. Because this article has 14 major sections, scan the headings first and then use the FAQ or summary sections to pressure-test the answer. That makes it a planning aid, not a replacement for medical advice.

  • Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
  • Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
  • Verify total monthly cost, refill timing, dose escalation pricing, and what is included before paying.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for All 5 FDA

For this provider comparisons page, the 2026 refresh focuses on semaglutide, tirzepatide, cash-pay pricing, safety signals, all, fda so the article stays close to the question behind "All 5 FDA".

The useful details are the practical ones: what to verify, what changes risk or cost, and which details separate All 5 FDA from nearby GLP-1, peptide, hormone, or provider-comparison searches.

Readers can use the added context to bring sharper questions to a licensed provider before making a treatment, cost, or care decision.

All 5 FDA custom 2026 image for provider comparisons on FormBlends

Custom 2026 image for All 5 FDA, provider comparisons, and better treatment decision-making.

Image description: Unique image for this page covering All 5 FDA, provider comparisons, safety, cost, provider selection, and patient decision-making.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Disclosure: FormBlends is one of the providers discussed in this article. Our editorial team independently researches and verifies all pricing and claims. Pricing was last verified in March 2026. Read our editorial policy.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.

Next Best Reads

Free Tools

Provider-informed calculators to support your weight loss journey.